## CBR-470-2

Cat. No.:	HY-134001	
CAS No.:	2416095-00-4	0
Molecular Formula:	C <sub>12</sub> H <sub>13</sub> Cl <sub>2</sub> NO <sub>6</sub> S <sub>2</sub>	но⊸(
Molecular Weight:	402.27	`—N∦
Target:	Keap1-Nrf2	$\left\langle \right\rangle$
Pathway:	NF-κB	0,5
Storage:	4°C, stored under nitrogen	
	* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)	

## SOLVENT & SOLUBILITY

		Concentration	1 mg	5 mg	10 mg	
	Preparing Stock Solutions	1 mM	2.4859 mL	12.4295 mL	24.8589 mL	
		5 mM	0.4972 mL	2.4859 mL	4.9718 mL	
		10 mM	0.2486 mL	1.2429 mL	2.4859 mL	
	Please refer to the solubility information to select the appropriate solvent.					

BIOLOGICAL ACTIV	
Description	CBR-470-2, a glycine-substituted analog, can activate NRF2 signaling. CBR-470-2 can be used for the research of modulation glycolysis <sup>[1]</sup> .
IC <sub>50</sub> & Target	NRF2 <sup>[1]</sup>
In Vitro	CBR-470-2 (1-10 μM; 24 h) increases transcript levels of the NRF2-responsive genes NQO1 and HMOX1 in epidermal keratinocytes and dermal fibroblasts <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	CBR-470-2 (50 mg/kg; p.o. twice daily for 10 d) induces activation of NRF2 signaling in vivo <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

0、,0

Ò

CI

CI



Animal Model:	Balb/C mice (5-week old) are exposed to UVB <sup>[1]</sup>
Dosage:	50 mg/kg
Administration:	P.o. twice daily for 10 days
Result:	Resulted in comparable beneficial effects on erythema histological scores and total wounded area. Decreased epidermal thickness in response to UV exposure.

## REFERENCES

[1]. Bollong MJ, et, al. A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling. Nature. 2018 Oct;562(7728):600-604.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA